Dezheng Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dezheng Lin has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Xuefeng Guo
State Key Laboratory of Coordination Chemistry Key Laboratory of Mesoscopic Chemistry MOE, School of Chemistry Nanjing University Nanjing P. R. China
5 shared publications Jiaxin Deng
Sun Yat-sen University
4 shared publicationsMingli Su
Sun Yat-sen University Sixth Affiliated Hospital, China
4 shared publications- Jiancong Hu
Department of Gastrointestinal Endoscopy, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
3 shared publications Jiancong Hu
Sun Yat-sen University
2 shared publicationsJuan Li
Sun Yat-sen University Sixth Affiliated Hospital, China
2 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (S 02) , E570-E571
Endoscopic ultrasound‑guided stricturotomy for complete anastomotic occlusion following Hartmann’s reversal
Complete anastomotic occlusion after colorectal surgery is rare but challenging, traditionally necessitating reoperation [1]. Although therapeutic endoscopy has been reported, it typically relies on endoscopic rendezvous techniques, which are inapplicable without a proximal stoma [2]. We herein report a case of complete anastomotic occlusion post-Hartmann’s reversal successfully treated with endoscopic ultrasound (EUS)‑guided stricturotomy. A 67-year-old man, 5 months after laparoscopic sigmoidectomy with Hartmann’s procedure for obstructive sigmoid colon cancer (pT3N0), underwent Hartmann’s reversal at our hospital. On postoperative day 4, he presented with abdominal pain ([Fig. 1] a). Computed tomography revealed anastomotic inflammatory edema causing near-total proximal colonic obstruction ([Fig. 1] b). Contrast study demonstrated complete anastomotic occlusion ([Fig. 1] c). We opted to perform EUS-guided stricturotomy. Initial colonoscopy confirmed complete colo-colonic anastomotic occlusion ([Fig. 2] a and [Video 1]). A linear echoendoscope was advanced to the obstruction’s anal side, with EUS demonstrating a dilated proximal bowel loop filled with fluid and particulate matter. After Doppler imaging confirmed no intervening vessels, the occluded anastomosis was punctured with a 19-gauge needle. Aspiration of the copious fecal material verified successful proximal bowel lumen access, and a 0.035-inch guidewire was inserted through the needle ([Fig. 2] b). Under wire guidance, a hook knife incised the stricture, achieving successful anastomotic recanalization with massive fecal evacuation ([Fig. 2] c). The colonoscope was advanced unimpeded through the patent anastomosis into the proximal colon ([Fig. 2] d). To ensure the correct direction and avoid perforation, the puncture site was set at the anastomotic midpoint, determined via EUS according to the anal and proximal bowel orientation, and incision was kept aligned with the guidewire. Post-procedure, the patient’s abdominal pain resolved completely. Upright abdominal radiography showed no obstruction or pneumoperitoneum ([Fig. 3]). He resumed normal diet and bowel function and was discharged in a stable condition. EUS‑guided stricturotomy may serve as a valuable therapeutic alternative for complete anastomotic strictures in which endoscopic rendezvous techniques are not applicable. Endoscopy_UCTN_Code_TTT_1AS_2AG Article published online: 05 May 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 2 April 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (S 02) , E570-E571
Open AccessEndoscopic ultrasound‑guided stricturotomy for complete anastomotic occlusion following Hartmann’s reversal
Complete anastomotic occlusion after colorectal surgery is rare but challenging, traditionally necessitating reoperation [1]. Although therapeutic endoscopy has been reported, it typically relies on endoscopic rendezvous techniques, which are inapplicable without a proximal stoma [2]. We herein report a case of complete anastomotic occlusion post-Hartmann’s reversal successfully treated with endoscopic ultrasound (EUS)‑guided stricturotomy. A 67-year-old man, 5 months after laparoscopic sigmoidectomy with Hartmann’s procedure for obstructive sigmoid colon cancer (pT3N0), underwent Hartmann’s reversal at our hospital. On postoperative day 4, he presented with abdominal pain ([Fig. 1] a). Computed tomography revealed anastomotic inflammatory edema causing near-total proximal colonic obstruction ([Fig. 1] b). Contrast study demonstrated complete anastomotic occlusion ([Fig. 1] c). We opted to perform EUS-guided stricturotomy. Initial colonoscopy confirmed complete colo-colonic anastomotic occlusion ([Fig. 2] a and [Video 1]). A linear echoendoscope was advanced to the obstruction’s anal side, with EUS demonstrating a dilated proximal bowel loop filled with fluid and particulate matter. After Doppler imaging confirmed no intervening vessels, the occluded anastomosis was punctured with a 19-gauge needle. Aspiration of the copious fecal material verified successful proximal bowel lumen access, and a 0.035-inch guidewire was inserted through the needle ([Fig. 2] b). Under wire guidance, a hook knife incised the stricture, achieving successful anastomotic recanalization with massive fecal evacuation ([Fig. 2] c). The colonoscope was advanced unimpeded through the patent anastomosis into the proximal colon ([Fig. 2] d). To ensure the correct direction and avoid perforation, the puncture site was set at the anastomotic midpoint, determined via EUS according to the anal and proximal bowel orientation, and incision was kept aligned with the guidewire. Post-procedure, the patient’s abdominal pain resolved completely. Upright abdominal radiography showed no obstruction or pneumoperitoneum ([Fig. 3]). He resumed normal diet and bowel function and was discharged in a stable condition. EUS‑guided stricturotomy may serve as a valuable therapeutic alternative for complete anastomotic strictures in which endoscopic rendezvous techniques are not applicable. Endoscopy_UCTN_Code_TTT_1AS_2AG Article published online: 05 May 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 20 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1247
Targeting the ZMYM2-ANXA9 Axis with FLT3 Inhibitor G749 Overcomes Oxaliplatin Resistance in Colorectal Cancer
Background: Chemoresistance and tumor recurrence remain major obstacles in colorectal cancer (CRC) therapy. Elucidating the molecular mechanisms underlying treatment resistance is critical for improving therapeutic outcomes. Methods: We analyzed transcriptomic profiles from public datasets (TCGA and GSE39582) to identify differentially expressed genes associated with a poor response to neoadjuvant chemotherapy in CRC patients. Among 298 candidate genes, ANXA9 emerged as significantly overexpressed in chemoresistant tumors and associated with a poor prognosis. These findings were further validated in an independent cohort of 146 Stage III CRC patients using immunohistochemistry and survival analysis. The expression of ANXA9 was evaluated in oxaliplatin acquired-resistant CRC cell lines via qPCR and Western blot. Functional studies, including RNA interference, colony formation, apoptosis assays, and drug sensitivity testing, were performed in vitro and in vivo to assess the role of ANXA9. A high-throughput drug screen identified G749, a FLT3 inhibitor, as a potential therapeutic agent. Results: ANXA9 expression was significantly elevated in non-responders to chemotherapy and oxaliplatin-resistant CRC cell lines. The knockdown of ANXA9 reduced proliferation and enhanced oxaliplatin sensitivity. G749 was found to suppress ANXA9 expression in a dose-dependent manner and inhibit CRC cell growth in vitro and in patient-derived organoids. In a CRC xenograft mouse model, G749 reduced the tumor burden without observable toxicity. Mechanistically, we identified ZMYM2 as a transcriptional regulator of ANXA9. ChIP-qPCR confirmed ZMYM2 binding to the ANXA9 promoter, especially in resistant cells. Silencing ZMYM2 suppressed tumor cell growth and restored chemosensitivity. Conclusions: The ZMYM2-ANXA9 signaling axis drives chemoresistance and tumor progression in CRC. FLT3 inhibition by G749 effectively downregulates ANXA9 and sensitizes tumors to chemotherapy, highlighting a novel therapeutic approach for chemoresistant CRC.
- 20 May 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1247
Open AccessTargeting the ZMYM2-ANXA9 Axis with FLT3 Inhibitor G749 Overcomes Oxaliplatin Resistance in Colorectal Cancer
Background: Chemoresistance and tumor recurrence remain major obstacles in colorectal cancer (CRC) therapy. Elucidating the molecular mechanisms underlying treatment resistance is critical for improving therapeutic outcomes. Methods: We analyzed transcriptomic profiles from public datasets (TCGA and GSE39582) to identify differentially expressed genes associated with a poor response to neoadjuvant chemotherapy in CRC patients. Among 298 candidate genes, ANXA9 emerged as significantly overexpressed in chemoresistant tumors and associated with a poor prognosis. These findings were further validated in an independent cohort of 146 Stage III CRC patients using immunohistochemistry and survival analysis. The expression of ANXA9 was evaluated in oxaliplatin acquired-resistant CRC cell lines via qPCR and Western blot. Functional studies, including RNA interference, colony formation, apoptosis assays, and drug sensitivity testing, were performed in vitro and in vivo to assess the role of ANXA9. A high-throughput drug screen identified G749, a FLT3 inhibitor, as a potential therapeutic agent. Results: ANXA9 expression was significantly elevated in non-responders to chemotherapy and oxaliplatin-resistant CRC cell lines. The knockdown of ANXA9 reduced proliferation and enhanced oxaliplatin sensitivity. G749 was found to suppress ANXA9 expression in a dose-dependent manner and inhibit CRC cell growth in vitro and in patient-derived organoids. In a CRC xenograft mouse model, G749 reduced the tumor burden without observable toxicity. Mechanistically, we identified ZMYM2 as a transcriptional regulator of ANXA9. ChIP-qPCR confirmed ZMYM2 binding to the ANXA9 promoter, especially in resistant cells. Silencing ZMYM2 suppressed tumor cell growth and restored chemosensitivity. Conclusions: The ZMYM2-ANXA9 signaling axis drives chemoresistance and tumor progression in CRC. FLT3 inhibition by G749 effectively downregulates ANXA9 and sensitizes tumors to chemotherapy, highlighting a novel therapeutic approach for chemoresistant CRC.
- Open Access
- 8 May 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2502138
Fusobacterium mortiferum and its metabolite 5-aminovaleric acid promote the development of colorectal cancer in obese individuals through Wnt/β-catenin pathway by DKK2
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, with high incidence and mortality rates. An increasing body of research suggests that obesity is a significant risk factor for the development of CRC. Moreover, recent findings have highlighted the close association between the gut microbiota and both obesity and CRC. Despite this, the specific mechanisms by which the gut microbiota influences obesity and CRC remain unclear. This study aims to explore the role of the gut bacterium Fusobacterium mortiferum and its metabolite 5-aminovaleric acid (5-AVA) in the development of obesity and CRC. Our study found that the metabolite 5-aminovaleric acid produced by Fusobacterium mortiferum significantly inhibits the expression of the tumor suppressor DKK2. This inhibition leads to enhanced proliferation of CRC cells. Furthermore, we discovered that Fusobacterium mortiferum and 5-AVA can activate the Wnt/β-catenin signaling pathway by inhibiting DKK2, thereby promoting tumor growth. This finding was validated in CRC mouse models and in vitro experiments. Additional mechanistic studies revealed that 5-AVA interacts with the demethylase KDM6B, affecting the demethylation process of DKK2 and subsequently activating the Wnt/β-catenin signaling pathway. Our study retrospectively collected fecal samples from patients who underwent gastrointestinal endoscopy at the Sixth Affiliated Hospital of Sun Yat-sen University over the past five years. Participants were stratified into a healthy control group and an adenoma group based on the outcomes of their colonoscopies. Following this, we conducted metagenomic analysis to identify differential bacteria, and based on the results, we performed bacterial cultivation and metabolomic profiling. The roles of the targeted bacteria and their metabolites were further validated through animal models and cellular assays, employing techniques such as Western Blot, qPCR, immunohistochemistry, molecular docking simulations, and gene overexpression studies. This study uncovers the potential carcinogenic effects of Fusobacterium mortiferum and 5-AVA in the development of obesity and CRC. Our research emphasizes the complex interplay between the gut microbiota and host metabolism and suggests new directions for future research to explore how modulation of the gut microbiota could prevent and treat CRC.
- 8 May 2025
- Published by Taylor & Francis in Gut Microbes
- Vol. 17 (1) , 2502138
Open AccessFusobacterium mortiferum and its metabolite 5-aminovaleric acid promote the development of colorectal cancer in obese individuals through Wnt/β-catenin pathway by DKK2
Colorectal cancer (CRC) is one of the most prevalent cancers worldwide, with high incidence and mortality rates. An increasing body of research suggests that obesity is a significant risk factor for the development of CRC. Moreover, recent findings have highlighted the close association between the gut microbiota and both obesity and CRC. Despite this, the specific mechanisms by which the gut microbiota influences obesity and CRC remain unclear. This study aims to explore the role of the gut bacterium Fusobacterium mortiferum and its metabolite 5-aminovaleric acid (5-AVA) in the development of obesity and CRC. Our study found that the metabolite 5-aminovaleric acid produced by Fusobacterium mortiferum significantly inhibits the expression of the tumor suppressor DKK2. This inhibition leads to enhanced proliferation of CRC cells. Furthermore, we discovered that Fusobacterium mortiferum and 5-AVA can activate the Wnt/β-catenin signaling pathway by inhibiting DKK2, thereby promoting tumor growth. This finding was validated in CRC mouse models and in vitro experiments. Additional mechanistic studies revealed that 5-AVA interacts with the demethylase KDM6B, affecting the demethylation process of DKK2 and subsequently activating the Wnt/β-catenin signaling pathway. Our study retrospectively collected fecal samples from patients who underwent gastrointestinal endoscopy at the Sixth Affiliated Hospital of Sun Yat-sen University over the past five years. Participants were stratified into a healthy control group and an adenoma group based on the outcomes of their colonoscopies. Following this, we conducted metagenomic analysis to identify differential bacteria, and based on the results, we performed bacterial cultivation and metabolomic profiling. The roles of the targeted bacteria and their metabolites were further validated through animal models and cellular assays, employing techniques such as Western Blot, qPCR, immunohistochemistry, molecular docking simulations, and gene overexpression studies. This study uncovers the potential carcinogenic effects of Fusobacterium mortiferum and 5-AVA in the development of obesity and CRC. Our research emphasizes the complex interplay between the gut microbiota and host metabolism and suggests new directions for future research to explore how modulation of the gut microbiota could prevent and treat CRC.
- Open Access
- 7 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 13 (CP) , a25923133
Epithelium-preserving stricturotomy is effective for improving postoperative benign anastomotic stricture associated with colorectal surgery
We analyzed a large sample of patients with colorectal cancer (CRC) treated with endoscopic stricturotomy (ESt) for postoperative benign anastomotic stricture (POBAS) and explored risk factors for stricture recurrence (restricture). We aimed to provide data on the long-term outcomes of ESt and support for optimizing ESt in treating and preventing POBAS recurrence.This retrospective study included 152 consecutive patients with CRC diagnosed with POBAS and treated by ESt at our center from April 2013 to April 2023. The primary outcome was stricture recurrence. Secondary outcomes were the technical success rate, postoperative adverse events (AEs), and restricture-free survival (RFS). Risk factors for stricture recurrence were explored.Of the 152 patients, 94.1% (143/152) achieved technical success after the first ESt. Twenty-two patients (17.5%) were diagnosed with recurrent stricture among 126 initial successful patients with follow-up. Anastomotic stricture length ≥ 1 cm and non-preservation of intestinal epithelium during ESt were independent risk factors for recurrence (P < 0.05). The cumulative RFS rate was 82.53%.Anastomotic stricture length ≥ 1 cm and non-epithelium preservatoin at ESt were independent risk factors for restricture after ESt in POBAS patients. These two factors may help predict risk of POBAS recurrence and provide reliable evidence for developing personalized treatment plans for patients.
- 7 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 13 (CP) , a25923133
Open AccessEpithelium-preserving stricturotomy is effective for improving postoperative benign anastomotic stricture associated with colorectal surgery
We analyzed a large sample of patients with colorectal cancer (CRC) treated with endoscopic stricturotomy (ESt) for postoperative benign anastomotic stricture (POBAS) and explored risk factors for stricture recurrence (restricture). We aimed to provide data on the long-term outcomes of ESt and support for optimizing ESt in treating and preventing POBAS recurrence.This retrospective study included 152 consecutive patients with CRC diagnosed with POBAS and treated by ESt at our center from April 2013 to April 2023. The primary outcome was stricture recurrence. Secondary outcomes were the technical success rate, postoperative adverse events (AEs), and restricture-free survival (RFS). Risk factors for stricture recurrence were explored.Of the 152 patients, 94.1% (143/152) achieved technical success after the first ESt. Twenty-two patients (17.5%) were diagnosed with recurrent stricture among 126 initial successful patients with follow-up. Anastomotic stricture length ≥ 1 cm and non-preservation of intestinal epithelium during ESt were independent risk factors for recurrence (P < 0.05). The cumulative RFS rate was 82.53%.Anastomotic stricture length ≥ 1 cm and non-epithelium preservatoin at ESt were independent risk factors for restricture after ESt in POBAS patients. These two factors may help predict risk of POBAS recurrence and provide reliable evidence for developing personalized treatment plans for patients.
- 23 August 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (10) , 6156-6160
Direct visualization endoscopic retrograde appendicitis therapy for treatment of acute uncomplicated appendicitis
Objective To investigate the diagnostic and therapeutic value of direct visualization (single-use eyeMax subscope) endoscopic management of acute uncomplicated appendicitis. Methods Thirty-six patients diagnosed with acute uncomplicated appendicitis, confirmed by computed tomography or ultrasonography, from Jan 2023 to Feb 2024 were enrolled in this study. We collected demographics, colonoscopy findings, subscope findings, clinical outcomes of endoscopic retrograde appendicitis therapy (ERAT), and adverse events associated with ERAT. Results Appendiceal intubation was successful for all 36 patients. Thirty-five patients (97.2%) were definitely confirmed as having acute uncomplicated appendicitis. One patient with negative appendicitis was diagnosed as having cecal diverticulitis with fecalith incarceration. The mean procedure time was 13.1 ± 13.6 min. One patient presented with worsening abdominal pain, and a computed tomography scan suggested a perforated appendix. The mean length of hospitalizations was 1.78 ± 2 days. The mean follow-up was 158 days; during this period, two patients (5.6%) experienced recurrent abdominal pain after 23 and 88 days and subsequently underwent laparoscopic appendectomy. Conclusion Direct visualization ERAT may be effective for diagnosing and treating acute uncomplicated appendicitis and seems to have a low complication rate. Graphical abstract
- 23 August 2024
- Published by Springer Nature in Surgical Endoscopy
- Vol. 38 (10) , 6156-6160
Direct visualization endoscopic retrograde appendicitis therapy for treatment of acute uncomplicated appendicitis
Objective To investigate the diagnostic and therapeutic value of direct visualization (single-use eyeMax subscope) endoscopic management of acute uncomplicated appendicitis. Methods Thirty-six patients diagnosed with acute uncomplicated appendicitis, confirmed by computed tomography or ultrasonography, from Jan 2023 to Feb 2024 were enrolled in this study. We collected demographics, colonoscopy findings, subscope findings, clinical outcomes of endoscopic retrograde appendicitis therapy (ERAT), and adverse events associated with ERAT. Results Appendiceal intubation was successful for all 36 patients. Thirty-five patients (97.2%) were definitely confirmed as having acute uncomplicated appendicitis. One patient with negative appendicitis was diagnosed as having cecal diverticulitis with fecalith incarceration. The mean procedure time was 13.1 ± 13.6 min. One patient presented with worsening abdominal pain, and a computed tomography scan suggested a perforated appendix. The mean length of hospitalizations was 1.78 ± 2 days. The mean follow-up was 158 days; during this period, two patients (5.6%) experienced recurrent abdominal pain after 23 and 88 days and subsequently underwent laparoscopic appendectomy. Conclusion Direct visualization ERAT may be effective for diagnosing and treating acute uncomplicated appendicitis and seems to have a low complication rate. Graphical abstract
- 19 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (6) , 1182
Application of Single-Use Subscope Imaging System in the Diagnosis and Treatment of Cecal Diverticulitis Misdiagnosed as Acute Appendicitis
- 19 July 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (6) , 1182
Application of Single-Use Subscope Imaging System in the Diagnosis and Treatment of Cecal Diverticulitis Misdiagnosed as Acute Appendicitis
- Open Access
- 30 January 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (6)
Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer
Resistance to neoadjuvant chemotherapy leads to poor prognosis of locally advanced rectal cancer (LARC), representing an unmet clinical need that demands further exploration of therapeutic strategies to improve clinical outcomes. Here, we identified a noncanonical role of RB1 for modulating chromatin activity that contributes to oxaliplatin resistance in colorectal cancer (CRC). We demonstrate that oxaliplatin induces RB1 phosphorylation, which is associated with the resistance to neoadjuvant oxaliplatin-based chemotherapy in LARC. Inhibition of RB1 phosphorylation by CDK4/6 inhibitor results in vulnerability to oxaliplatin in both intrinsic and acquired chemoresistant CRC. Mechanistically, we show that RB1 modulates chromatin activity through the TEAD4/HDAC1 complex to epigenetically suppress the expression of DNA repair genes. Antagonizing RB1 phosphorylation through CDK4/6 inhibition enforces RB1/TEAD4/HDAC1 repressor activity, leading to DNA repair defects, thus sensitizing oxaliplatin treatment in LARC. Our study identifies a RB1 function in regulating chromatin activity through TEAD4/HDAC1. It also provides the combination of CDK4/6 inhibitor with oxaliplatin as a potential synthetic lethality strategy to mitigate oxaliplatin resistance in LARC, whereby phosphorylated RB1/TEAD4 can serve as potential biomarkers to guide the patient stratification.
- 30 January 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (6)
Open AccessPharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer
Resistance to neoadjuvant chemotherapy leads to poor prognosis of locally advanced rectal cancer (LARC), representing an unmet clinical need that demands further exploration of therapeutic strategies to improve clinical outcomes. Here, we identified a noncanonical role of RB1 for modulating chromatin activity that contributes to oxaliplatin resistance in colorectal cancer (CRC). We demonstrate that oxaliplatin induces RB1 phosphorylation, which is associated with the resistance to neoadjuvant oxaliplatin-based chemotherapy in LARC. Inhibition of RB1 phosphorylation by CDK4/6 inhibitor results in vulnerability to oxaliplatin in both intrinsic and acquired chemoresistant CRC. Mechanistically, we show that RB1 modulates chromatin activity through the TEAD4/HDAC1 complex to epigenetically suppress the expression of DNA repair genes. Antagonizing RB1 phosphorylation through CDK4/6 inhibition enforces RB1/TEAD4/HDAC1 repressor activity, leading to DNA repair defects, thus sensitizing oxaliplatin treatment in LARC. Our study identifies a RB1 function in regulating chromatin activity through TEAD4/HDAC1. It also provides the combination of CDK4/6 inhibitor with oxaliplatin as a potential synthetic lethality strategy to mitigate oxaliplatin resistance in LARC, whereby phosphorylated RB1/TEAD4 can serve as potential biomarkers to guide the patient stratification.
- Open Access
- 21 July 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Safety and feasibility of neoadjuvant chemotherapy as a surgical bridge for acute left-sided malignant colorectal obstruction: a retrospective study
Background: For colorectal cancer, preoperative (neoadjuvant) chemotherapy is more effective than postoperative chemotherapy because it not only eradicates micrometastases more effectively but also reduces the risk of incomplete intraoperative resection and tumor cell shedding. For the treatment of acute left-sided malignant colorectal obstruction, colorectal stents as well as stoma are being used to relieve the obstructive colorectal cancer, and as a bridge to surgery, allowing easy mobilization and resection of the colon. Neoadjuvant chemotherapy combined with self-expandable metal stents (SEMS) or neoadjuvant chemotherapy combined with decompressing stoma (DS) can be used as a bridge to elective surgery (BTS) as an alternative to emergency surgery in patients with acute left-sided malignant colorectal obstruction, but its benefit is uncertain. The purpose of this study was to evaluate the safety and feasibility of neoadjuvant chemotherapy as a bridge to surgery in the treatment of acute left-sided malignant colorectal obstruction. Methods: Data from patients who were admitted with acute left-sided malignant colorectal obstruction between January 2012 and December 2020 were retrospectively reviewed, and patients with gastrointestinal perforation or peritonitis were excluded. We performed one-to-two propensity score matching to compare the stoma requirement, postoperative complications, and other short-term oncological outcomes between the neoadjuvant chemotherapy group and surgery group. Results: There were no differences in intraoperative blood loss, operative time, one-year postoperative mortality, and postoperative tumor markers between the two groups. The 1-year recurrence-free survival (RFS) rates of neoadjuvant chemotherapy group and surgery group were 96.8 and 91.3% (p = 0.562). The neoadjuvant chemotherapy group was able to reduce stoma rate 1 year after surgery (p = 0.047). Besides, the neoadjuvant group significantly reduced postoperative bowel function time (p < 0.001), postoperative hospital stay (p < 0.001), total hospital stay (p = 0.002), postoperative complications (p = 0.017), reduction in need to stay in the intensive care unit (ICU) (p = 0.042). Conclusions: Neoadjuvant chemotherapy as a bridge to elective surgery in patients with acute left-sided malignant colorectal obstruction is safe and has many advantages. Prospective multicenter studies with large samples are needed to further evaluate the feasibility of neoadjuvant chemotherapy.
- 21 July 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Open AccessSafety and feasibility of neoadjuvant chemotherapy as a surgical bridge for acute left-sided malignant colorectal obstruction: a retrospective study
Background: For colorectal cancer, preoperative (neoadjuvant) chemotherapy is more effective than postoperative chemotherapy because it not only eradicates micrometastases more effectively but also reduces the risk of incomplete intraoperative resection and tumor cell shedding. For the treatment of acute left-sided malignant colorectal obstruction, colorectal stents as well as stoma are being used to relieve the obstructive colorectal cancer, and as a bridge to surgery, allowing easy mobilization and resection of the colon. Neoadjuvant chemotherapy combined with self-expandable metal stents (SEMS) or neoadjuvant chemotherapy combined with decompressing stoma (DS) can be used as a bridge to elective surgery (BTS) as an alternative to emergency surgery in patients with acute left-sided malignant colorectal obstruction, but its benefit is uncertain. The purpose of this study was to evaluate the safety and feasibility of neoadjuvant chemotherapy as a bridge to surgery in the treatment of acute left-sided malignant colorectal obstruction. Methods: Data from patients who were admitted with acute left-sided malignant colorectal obstruction between January 2012 and December 2020 were retrospectively reviewed, and patients with gastrointestinal perforation or peritonitis were excluded. We performed one-to-two propensity score matching to compare the stoma requirement, postoperative complications, and other short-term oncological outcomes between the neoadjuvant chemotherapy group and surgery group. Results: There were no differences in intraoperative blood loss, operative time, one-year postoperative mortality, and postoperative tumor markers between the two groups. The 1-year recurrence-free survival (RFS) rates of neoadjuvant chemotherapy group and surgery group were 96.8 and 91.3% (p = 0.562). The neoadjuvant chemotherapy group was able to reduce stoma rate 1 year after surgery (p = 0.047). Besides, the neoadjuvant group significantly reduced postoperative bowel function time (p < 0.001), postoperative hospital stay (p < 0.001), total hospital stay (p = 0.002), postoperative complications (p = 0.017), reduction in need to stay in the intensive care unit (ICU) (p = 0.042). Conclusions: Neoadjuvant chemotherapy as a bridge to elective surgery in patients with acute left-sided malignant colorectal obstruction is safe and has many advantages. Prospective multicenter studies with large samples are needed to further evaluate the feasibility of neoadjuvant chemotherapy.
- 4 May 2021
- Published by Springer Nature in European Surgery
- Vol. 54 (4) , 189-194
Short-term outcomes of laparoscopic complete mesocolic excision versus noncomplete mesocolic excision for right colon cancer: a systematic review and meta-analysis
- 4 May 2021
- Published by Springer Nature in European Surgery
- Vol. 54 (4) , 189-194
Short-term outcomes of laparoscopic complete mesocolic excision versus noncomplete mesocolic excision for right colon cancer: a systematic review and meta-analysis